Rivastigmine Transdermal System Patch, Extended Release
Product Images NDC 63629-8846

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Rivastigmine Transdermal System (NDC 63629-8846). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (Lbl636298846)

Label (Lbl636298846)
This is a description of Rivastigmine Transdermal System with 13.3 mg per 24 hours, sold in a 30 system pack. It provides instructions for use, including wearing only one patch at a time, changing the patch every 24 hours, and not cutting it. It also warns to keep out of reach of children and that it's only for transdermal use. The product should be stored at a temperature range of 15°C-30°C and the NDC code is 63629-8846-1.*
FDA Label Image

Chemical Structure (Rivastigmine 01)

Chemical Structure (Rivastigmine 01)
FDA Label Image

Figure 1 (Rivastigmine 02)

Figure 1 (Rivastigmine 02)
FDA Label Image

Figure 2 (Rivastigmine 03)

Figure 2 (Rivastigmine 03)
This text shows the concentration of Rivastigmine in ng/mL for different doses of the drug (13.3 mg/24 hours, 9.5 mg/24 hours, and 4.6 mg/24 hours) and the number of participants (n) in each group (19, 22, and 22, respectively). It appears to be part of a study or clinical trial.*
FDA Label Image

Figure 3 (Rivastigmine 04)

Figure 3 (Rivastigmine 04)
FDA Label Image

Figure 4 (Rivastigmine 05)

Figure 4 (Rivastigmine 05)
FDA Label Image

Figure 5 (Rivastigmine 06)

Figure 5 (Rivastigmine 06)
FDA Label Image

Figure 6 (Rivastigmine 07)

Figure 6 (Rivastigmine 07)
FDA Label Image

Figure 7 (Rivastigmine 08)

Figure 7 (Rivastigmine 08)
This is a statistical analysis report comparing the efficacy of two treatments using LS mean diff and improvement. The treatments are Rivastigmine Transdermal System 15 cm² and Rivastigmine Transdermal System 5 cm² over 8, 16 and 24 weeks. The report provides statistical significance (p-values) for the analysis. The LS means and standard errors are also given.*
FDA Label Image

Figure 8 (Rivastigmine 09)

Figure 8 (Rivastigmine 09)
This is a description of a clinical study that evaluated the effects of Rivastigmine Transdermal System (15 cm2 and 5 cm2) on cognitive function over a period of 16 weeks. The study used a statistical analysis of covariance model to determine least squares means (LS means) and standard errors of the LS means (STE) adjusted for pooled center and baseline. The study results indicate that the treatment did not show statistical significance in improving cognitive function at a level of 0.05.*
FDA Label Image

Figure A (Rivastigmine 10)

Figure A (Rivastigmine 10)
FDA Label Image

Figure B (Rivastigmine 11)

Figure B (Rivastigmine 11)
FDA Label Image

Figure C (Rivastigmine 12)

Figure C (Rivastigmine 12)
FDA Label Image

Figure D (Rivastigmine 13)

Figure D (Rivastigmine 13)
FDA Label Image

Figure E (Rivastigmine 14)

Figure E (Rivastigmine 14)
FDA Label Image

Figure F (Rivastigmine 15)

Figure F (Rivastigmine 15)
FDA Label Image

Figure G (Rivastigmine 16)

Figure G (Rivastigmine 16)
FDA Label Image

Figure H (Rivastigmine 17)

Figure H (Rivastigmine 17)
This appears to be a set of instructions for discarding a patch, which should be folded with its sticky sides together and placed in the trash. The user is instructed to first fold the patch, and then place it in an empty pouch (that they have saved). Finally, there is a cautionary note to keep the patch away from children and pets.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.